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Background
The variability of HIV and the appearance of escape
mutants are a major obstacle for HIV/AIDS vaccine devel-
opment. In previous phase I/II studies recombinant MVA-
Nef and MVA-BN®-Polytope expressing conserved
epitopes from multiple proteins of HIV-1 induced good
and broad cellular immune responses and indicated an
inhibitory effect on viral replication during treatment
interruption (MVA-Nef). To further broaden the immune
responses a new MVA-BN®-Multiantigen vaccine candi-
date expressing full length or truncated HIV-1 proteins
(gag, pol, nef, tat, vpr, vpu, vif, rev) has been developed
and tested for safety and immunogenicity.
Methods
Fifteen HIV-1 infected patients on HAART therapy with
CD4 counts above 350/μl received 2 × 108 TCID50 MVA-
BN®-Multiantigen at weeks 0, 4 and 12. Cellular immune
responses against HIV-1 proteins were measured by IFN-
gamma ELISPOT from PBMC preparations. Peptide pools
consisted of overlapping peptides: three pools each for
gag and pol, four pools for nef and three pools for the
remaining proteins.
Results
13 out of 15 (87%) of the subjects generated new or
increased HIV specific responses following vaccination
independent of their vaccinia prevaccination status.
Amongst these subjects 77% (10/13) elicited a response
to at least two and 54% (7/13) to at least three HIV pro-
teins. Gag induced the highest magnitude and responder
rate. No response was seen against tat and vif.
Conclusion
This MVA-BN®-Multiantigen vaccine induced broad cellu-
lar immune responses in HIV-1 infected individuals
against most of the expressed HIV proteins in the presence
of existing anti-vector immunity. The high number of
responders is encouraging and warrants further studies.
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